Skip to main content
Premium Trial:

Request an Annual Quote

Hoping to Spur Biotech Business Partnering With US Firms, Japanese Gov t Sponsors Week-long Event

NEW YORK, March 4 (GenomeWeb News) - US-based genomics-tool companies and drug makers eager to expand their footprint in Japan can take part in a week-long business-partnering program in Japan sponsored by the Japanese government.

 

Held on May 15-21 in Tokyoand Nagoya, the program is designed to "help US companies best assess market opportunities and develop partnerships and alliances," according to the Japan External Trade Organization.

 

Many genomic-tool companies in the United Statessay the Japanese market for their technologies is large, growing, and increasingly important, and Japan's government hopes to use this meeting to convey its interest in forging trans-Pacific alliances in biotech and other industries.

 

"The investment climate in Japanhas undergone significant changes over the past several years," JETRO said in a statement. "The Japanese government has initiated major policy and legislative changes to open up markets, accelerate business investment decisions and reduce transaction costs.

 

"Many obstacles to foreign investment have been removed. Land prices, public utility charges, labor costs, interest rates and taxes have decreased, which has generated increased returns for investment and strengthened Japan's competitive positioning in the global markets," the government agency added.

 

Companies from various industries are scheduled to participate, including Japanese biomedical concerns, including Amano Enzyme, Fujisawa Pharmaceutical, Japan Tissue Engineering, Japan Tobacco, Meito Sangyo, Mitsubishi Chemical, Otsuka Pharmaceutical, Sanwa Chemical, Suzuken, Taiwa Pharmaceutical, Takara Bio, Tokai Medical Products, Toyobo, Asahi Kasei, Chugai Pharmaceuticals, Daiichi Pharmaceutical, Eisai, Kyowa Hakko, Summit Pharmaceuticals International, Takeda Pharmaceutical, and Yamanouchi Pharmaceutical.

 

The program includes sessions on market assessment, business reforms, and recent regulatory changes.

 

Additional information about the meeting can be found here.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more